Ovagen (AED) – 20mg | Reproductive & Ovarian Tissue Research Compound

Ovagen is a synthetic tripeptide bioregulator with the sequence Ala-Glu-Asp (AED), developed within the Khavinson Cytogen peptide series at the St. Petersburg Institute of Bioregulation and Gerontology. It is classified as the reproductive-tissue-targeted member of the Cytogen family, joining Cardiogen (cardiac), Cartalax (cartilage), Cortagen (CNS), and Crystagen (immune/thymic) as tissue-specific short peptide bioregulators studied for their proposed gene-regulatory rather than receptor-mediated mechanisms.

Key Research Areas:

• Ovarian & Reproductive Tissue Gene Regulation — As a Cytogen-class peptide, Ovagen’s AED sequence is proposed to interact with nuclear DNA regulatory regions in ovarian tissue, consistent with the broader Khavinson hypothesis that short peptide bioregulators act by modulating tissue-specific gene expression programs rather than through classical receptor-ligand binding.
• Reproductive Cellular Signaling Research — Research interest in Ovagen centers on its potential relationship with cellular signaling and gene-expression pathways in reproductive tissue models, an area of research shared across the Cytogen series.
• Comparative Cytogen Mechanism Research — Because Ovagen shares its core AED sequence with Cartalax, laboratory research in this area often draws mechanistic comparisons across Cytogen peptides to understand how identical core sequences may produce tissue-differentiated effects depending on cellular context and co-factors present in target tissue.

Product Specifications:

• Sequence: Ala-Glu-Asp (AED)
• 20mg lyophilized powder per vial
• ≥99% purity via HPLC, third-party COA available
• Store refrigerated (2–8°C) or frozen for long-term storage; protect from light and moisture

For laboratory and research use only. Not intended for human or animal consumption, diagnostic, or therapeutic use. Not a drug, dietary supplement, or cosmetic.